National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 7) (PB 63 of 2019) (Cth)

PB 63 of 2019

National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 7)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated             26   July 2019

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 7).

(2)   This Determination may also be cited as PB 63 of 2019.

1. Commencement

This Determination commences on 1 August 2019.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Apraclonidine

Omit

Aprepitant

[2]     Schedule 1, after item dealing with Flupentixol decanoate

Omit

Fluticasone furoate with vilanterol

Insert

Fluticasone furoate

[3]     Schedule 1, after item dealing with Hydrochlorothiazide

Omit

Hydromorphone

[4]     Schedule 1, after item dealing with Tranylcypromine

Omit

Trastuzumab

[5]     Schedule 2, after item dealing with Hydrocortisone

Insert

Hydromorphone

[6]     Schedule 2, after item dealing with Tenofovir with emtricitabine

Insert

Tenofovir with emtricitabine and efavirenz

[7]     Schedule 2, after item dealing with Tranexamic acid

Insert

Trastuzumab